These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 9176707)

  • 21. Accelerated rejection of Fas ligand-expressing heart grafts.
    Takeuchi T; Ueki T; Nishimatsu H; Kajiwara T; Ishida T; Jishage K; Ueda O; Suzuki H; Li B; Moriyama N; Kitamura T
    J Immunol; 1999 Jan; 162(1):518-22. PubMed ID: 9886428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroimmunomodulation and immune privilege: the role of neuropeptides in ocular immunosuppression.
    Taylor AW
    Neuroimmunomodulation; 2002-2003; 10(4):189-98. PubMed ID: 12584406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. See no evil, hear no evil, do no evil: the lessons of immune privilege.
    Niederkorn JY
    Nat Immunol; 2006 Apr; 7(4):354-9. PubMed ID: 16550198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fas ligand-induced apoptosis as a mechanism of immune privilege.
    Griffith TS; Brunner T; Fletcher SM; Green DR; Ferguson TA
    Science; 1995 Nov; 270(5239):1189-92. PubMed ID: 7502042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ocular immunosuppressive microenvironment.
    Taylor AW
    Chem Immunol; 1999; 73():72-89. PubMed ID: 10590575
    [No Abstract]   [Full Text] [Related]  

  • 26. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.
    Bennett MW; O'connell J; O'sullivan GC; Roche D; Brady C; Kelly J; Collins JK; Shanahan F
    Gut; 1999 Feb; 44(2):156-62. PubMed ID: 9895372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trophoblasts express Fas ligand: a proposed mechanism for immune privilege in placenta and maternal invasion.
    Uckan D; Steele A; Cherry ; Wang BY; Chamizo W; Koutsonikolis A; Gilbert-Barness E; Good RA
    Mol Hum Reprod; 1997 Aug; 3(8):655-62. PubMed ID: 9294848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction.
    Kang SM; Schneider DB; Lin Z; Hanahan D; Dichek DA; Stock PG; Baekkeskov S
    Nat Med; 1997 Jul; 3(7):738-43. PubMed ID: 9212099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inflammatory signals increase Fas ligand expression by inner ear cells.
    Bodmer D; Brors D; Pak K; Keithley EM; Mullen L; Ryan AF; Gloddek B
    J Neuroimmunol; 2002 Aug; 129(1-2):10-7. PubMed ID: 12161015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apoptotic depletion of infiltrating mucosal lymphocytes associated with Fas ligand expression by Helicobacter pylori-infected gastric mucosal epithelium: human glandular stomach as a site of immune privilege.
    Koyama S
    Dig Dis Sci; 2000 Apr; 45(4):773-80. PubMed ID: 10759249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune privilege or inflammation? Insights into the Fas ligand enigma.
    O'Connell J; Houston A; Bennett MW; O'Sullivan GC; Shanahan F
    Nat Med; 2001 Mar; 7(3):271-4. PubMed ID: 11231613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.
    Restifo NP
    Nat Med; 2000 May; 6(5):493-5. PubMed ID: 10802692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack.
    Maher S; Toomey D; Condron C; Bouchier-Hayes D
    Immunol Cell Biol; 2002 Apr; 80(2):131-7. PubMed ID: 11940113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues.
    Xerri L; Devilard E; Hassoun J; Mawas C; Birg F
    Mol Pathol; 1997 Apr; 50(2):87-91. PubMed ID: 9231156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TRAIL: a mechanism of tumor surveillance in an immune privileged site.
    Lee HO; Herndon JM; Barreiro R; Griffith TS; Ferguson TA
    J Immunol; 2002 Nov; 169(9):4739-44. PubMed ID: 12391182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Fas, fas ligand, immune tolerance, and cancer: implications in cancer of the colon].
    Berger A; Piqueras B; Pages F; Tartour E; Cugnenc PH; Fridman WH
    Bull Cancer; 1998 Feb; 85(2):129-33. PubMed ID: 9752329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression.
    Delgado M; Ganea D
    J Immunol; 2000 Jul; 165(1):114-23. PubMed ID: 10861043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3.
    Delgado M; Ganea D
    J Immunol; 2001 Jan; 166(2):1028-40. PubMed ID: 11145682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen.
    Mor G; Kohen F; Garcia-Velasco J; Nilsen J; Brown W; Song J; Naftolin F
    J Steroid Biochem Mol Biol; 2000; 73(5):185-94. PubMed ID: 11070347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells.
    Li JH; Rosen D; Sondel P; Berke G
    Immunology; 2002 Mar; 105(3):267-77. PubMed ID: 11918688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.